BCS Private Wealth Management Inc. Buys 54,159 Shares of Kenvue Inc. $KVUE

BCS Private Wealth Management Inc. boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 379.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,434 shares of the company’s stock after purchasing an additional 54,159 shares during the quarter. BCS Private Wealth Management Inc.’s holdings in Kenvue were worth $1,111,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Kenvue by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after buying an additional 4,101,880 shares during the last quarter. Geode Capital Management LLC boosted its stake in Kenvue by 1.2% in the second quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock valued at $1,021,267,000 after acquiring an additional 604,953 shares in the last quarter. Independent Franchise Partners LLP grew its holdings in Kenvue by 233.4% in the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after purchasing an additional 21,886,537 shares during the last quarter. American Century Companies Inc. grew its stake in Kenvue by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock worth $633,447,000 after buying an additional 8,436,166 shares during the last quarter. Finally, Norges Bank purchased a new position in Kenvue during the 2nd quarter worth $537,418,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE:KVUE opened at $17.13 on Thursday. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The firm has a market cap of $32.81 billion, a price-to-earnings ratio of 22.83 and a beta of 0.60. The firm’s fifty day moving average is $16.95 and its two-hundred day moving average is $18.32.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. During the same quarter last year, the business posted $0.28 EPS. The company’s revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s payout ratio is currently 110.67%.

Insider Activity

In other news, Director Jeffrey C. Smith acquired 3,200,000 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was acquired at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the transaction, the director owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. The trade was a 13.27% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.68% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on KVUE. Rothschild Redb upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. Citigroup decreased their price objective on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. Jefferies Financial Group lowered their target price on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Monday, October 27th. UBS Group cut their price target on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Finally, Bank of America decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Kenvue has an average rating of “Hold” and an average price target of $20.23.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.